GlassScriptPhysician profile
James W Bell
NPI 1265859508
$3,048.65
in general payments reported to CMS, 2019-2025
19 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $633 · 2024: $1,121 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,048.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $387.76 | 2024-2025 | Xyosted |
| E.R. Squibb & Sons, L.L.C. | $367.98 | 2024-2025 | Camzyos, Eliquis |
| Endo Pharmaceuticals INC. | $315.96 | 2023-2024 | Xiaflex, Aveed |
| Endo USA, INC. | $301.19 | 2024-2025 | Xiaflex, Aveed |
| Pfizer INC. | $281.07 | 2023-2025 | |
| Novo Nordisk INC | $230.46 | 2023-2025 | Wegovy, Ozempic |
| Tolmar, INC. | $190.82 | 2023-2025 | Jatenzo |
| Lilly USA, LLC | $179.87 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $175.78 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $143.91 | 2024-2025 | |
| Esperion Therapeutics, INC. | $138.23 | 2023-2025 | Nexletol |
| Heartflow, INC. | $84.68 | 2023-2025 | Ffrct |
| Halozyme INC | $79.07 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.62 | 2025 | |
| Inspire Medical Systems, INC. | $33.10 | 2025 | Inspire |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $26.46 | 2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $24.79 | 2024 | Xarelto |
| Echosens North America, INC. | $16.07 | 2025 | Fibroscan |
| Currax Pharmaceuticals LLC | $15.83 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.